Dernières nouvelles pour Saverone 2014 (NASDAQ:SVRE) Stock

Saverone 2014

Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.

SaverOne 2014 Ltd. - American Depositary Shares

Saverone 2014 Ltd

WIIM

Dyne Therapeutics shares are trading higher. The company reported Q1 financial results.

RBC Capital analyst Gregory Renza maintains BeiGene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) with a Outperform and lowers the price target from $312 to $311.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on BeiGene, Lowers Price Target to $311

WBD stock has given up its prior loss. Warner Bros Discovery shares were trading lower following Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock moved upwards by 174.5% to $7.0 during Thursday's regular session. The company's market cap stands at $10.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares moved upwards by 35.98% to $23.09. The market value of their outstanding shares is at $919.2 million. The company's, Q1 earnings came out yesterday. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) shares moved upwards by 29.7% to $7.92. The market value of their outstanding shares is at $267.4 million. </li>
<li>Classover Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>) stock moved upwards by 26.25% to $5.77. The company's market cap stands at $128.4 million. </li>
<li>Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) stock rose 22.02% to $10.45. The company's market cap stands at $312.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Jumia Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NYSE">JMIA</a>) shares rose 21.04% to $2.9. The company's market cap stands at $355.7 million. As per the press release, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGP#NASDAQ">QVCGP</a>) shares fell 38.9% to $16.99 during Thursday's regular session. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares decreased by 33.47% to $0.13. The company's market cap stands at $52.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Krispy Kreme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) stock decreased by 27.37% to $3.15. The market value of their outstanding shares is at $536.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares declined by 16.67% to $0.01. </li>
<li>Zapp Electric Vehicles Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) shares declined by 14.86% to $0.38. The market value of their outstanding shares is at $2.9 million. </li>
<li>Lucky Strike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUCK#NYSE">LUCK</a>) stock declined by 14.11% to $8.22. The company's market cap stands at $1.2 billion. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DNUT

GNLN

GRPN

JMIA

KIDZ

LUCK

PBPB

QVCGA

QVCGP

RYET

VEEE

ZAPP

12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) stock rose 147.8% to $8.4 during Thursday's regular session. The market value of their outstanding shares is at $114.6 million. </li>
<li>QMMM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) shares moved upwards by 40.2% to $1.02. The market value of their outstanding shares is at $17.5 million. </li>
<li>DHI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHX#NYSE">DHX</a>) stock increased by 29.41% to $1.76. The company's market cap stands at $84.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) stock increased by 23.91% to $5.44. The market value of their outstanding shares is at $561.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Anghami (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGH#NASDAQ">ANGH</a>) stock increased by 21.56% to $0.62. The company's market cap stands at $41.4 million. </li>
<li>Gray Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTN#NYSE">GTN</a>) shares rose 19.23% to $4.44. The company's market cap stands at $451.8 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) shares decreased by 22.4% to $4.32 during Thursday's regular session. The market value of their outstanding shares is at $854.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) stock declined by 21.91% to $4.29. The company's market cap stands at $850.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>GCL Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) stock declined by 14.12% to $2.13. The market value of their outstanding shares is at $268.9 million. </li>
<li>Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) shares decreased by 12.23% to $5.1. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. </li>
<li>QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) stock decreased by 10.32% to $16.39. The market value of their outstanding shares is at $925.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>GDEV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>) shares declined by 9.92% to $15.09. The company's market cap stands at $273.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGH

ASST

BMBL

GDEV

LILA

LILAK

QMMM

QNST

STGW

12 Communication Services Stocks Moving In Thursday's Intraday Session

Mizuho analyst Ben Chaiken maintains Light &amp; Wonder (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) with a Underperform and raises the price target from $80 to $84.

Mizuho Maintains Underperform on Light & Wonder, Raises Price Target to $84

<h3>Gainers</h3>
<ul>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) shares rose 39.1% to $35.96 during Thursday's regular session. The company's market cap stands at $2.4 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 38.08% to $6.54. The company's market cap stands at $355.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) stock increased by 32.83% to $15.6. The company's market cap stands at $276.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) stock increased by 24.11% to $14.41. The market value of their outstanding shares is at $481.3 million. As per the press release, Q1 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock moved upwards by 22.84% to $2.85. The market value of their outstanding shares is at $107.1 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock increased by 21.64% to $6.88. The company's market cap stands at $343.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 74.5% to $0.12 during Thursday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 69.32% to $0.16. The company's market cap stands at $20.5 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock decreased by 64.04% to $0.11. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 43.31% to $0.23. The market value of their outstanding shares is at $11.8 million. </li>
<li>Advanced Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) stock fell 29.1% to $1.17. The market value of their outstanding shares is at $25.3 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares fell 28.83% to $3.44. The market value of their outstanding shares is at $123.9 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVB

AXDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CYRX

DCTH

GNLX

NCNA

QDEL

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares increased by 46.3% to $0.14 during Thursday's regular session. The market value of their outstanding shares is at $18.7 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares moved upwards by 27.8% to $2.39. The company's market cap stands at $289.0 million. </li>
<li>BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) shares increased by 27.46% to $11.14. The market value of their outstanding shares is at $349.3 million. As per the news, the Q1 earnings report came out today. </li>
<li>LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) shares increased by 27.1% to $9.21. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Tutor Perini (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) shares increased by 27.02% to $30.02. The company's market cap stands at $1.5 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) shares rose 26.15% to $1.33. The company's market cap stands at $21.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) stock fell 24.0% to $7.45 during Thursday's regular session. </li>
<li>Energy Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERII#NASDAQ">ERII</a>) stock declined by 22.08% to $11.72. The company's market cap stands at $641.7 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) shares declined by 18.44% to $7.7. The market value of their outstanding shares is at $238.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWSN#NYSE">BWSN</a>) shares declined by 18.23% to $11.58. </li>
<li>AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) stock declined by 15.2% to $5.97. The market value of their outstanding shares is at $279.7 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) stock decreased by 14.25% to $1.42. The company's market cap stands at $30.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASLE

BlackSky Technology Inc. Class A Common Stock

BKSY

BWNB

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026

BWSN

DXST

ERII

HTCO

NCEW

12 Industrials Stocks Moving In Thursday's Intraday Session

Liberty Latin America shares are trading lower after the company reported worse-than-expected Q1 financial results.

Barclays analyst Betty Jiang maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Equal-Weight and raises the price target from $46 to $48.

Barclays Maintains Equal-Weight on Occidental Petroleum, Raises Price Target to $48

Energy Recovery shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, B. Riley Securities downgraded the stock from Buy to Neutral and lowered its price target from $20 to $12.5

RBC Capital analyst Arun Viswanathan maintains Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) with a Outperform and raises the price target from $62 to $63.

BALL

RBC Capital Maintains Outperform on Ball, Raises Price Target to $63

Barclays analyst Trevor Young maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Overweight and raises the price target from $2500 to $3100.

MELI

Barclays Maintains Overweight on MercadoLibre, Raises Price Target to $3100

Barclays analyst Benjamin Budish maintains MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Equal-Weight and raises the price target from $232 to $240.

MKTX

Barclays Maintains Equal-Weight on MarketAxess Holdings, Raises Price Target to $240

JPMorgan analyst Arun Jayaram anticipates a neutral market reaction to Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">earnings</a>.
Jayaram explained in a Thursday research note that positive results, debt reduction, and cost-saving initiatives were partly offset by potential risks to full-year guidance related to U.S. operating expenses and Gulf of Anadarko (GoA) volumes.
Jayaram&#8217;s forecast comes after Occidental reported adjusted EPS of 87 cents per share, which beat the analyst consensus estimate of 77 cents and revenue of $6.84 billion, which missed the analyst <a href="https://www.benzinga.com/25/05/45290926/occidental-beats-q1-profit-forecast-slashes-debt-by-23-billion-year-to-date" target="_blank" rel="noreferrer noopener">consensus estimate of $6.89 billion</a>.
The company sees production of 1,377 – 1,417 Mboed in the second quarter and 1,390 – 1,440 Mboed&nbsp;<a href="https://www.oxy.com/siteassets/documents/investors/quarterly-earnings/oxy1q25conferencecallslides.pdf" target="_blank" rel="noreferrer noopener">in&nbsp;</a>FY25.
Occidental also slashed the mid-point of 2025 capital guidance by $200 million and domestic operating costs by $150 million, on continued operational efficiency gains and schedule optimization <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">in the Permian and Gulf of America</a>.
So far, second-quarter 2025 guidance slightly trails JPMorgan expectations.
Jayaram notes that Occidental anticipates total production volumes in the GoA to reach 142 thousand barrels of oil equivalent per day (MBoe/d) for 2025.
Achieving this target would necessitate a significant increase in production during the second half of the year to approximately 158 MBoe/d, which is about 26% higher than the projected first-half 2025 average of 126 MBoe/d, adds the analyst.
Jayaram considers this a challenging goal, especially given the reduced capital allocation to offshore projects.
The analyst estimates the second-quarter total production of 1,413 Mboed (vs. street view of 1,420 Mboed) and FY25 production of 1,415 Mboed (same as consensus).
Investors can gain exposure to the stock via&nbsp;Texas Capital Funds Trust Texas Capital Texas Oil Index ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OILT#NYSE">OILT</a>) and&nbsp;First Trust Nasdaq Oil &amp; Gas ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXN#NASDAQ">FTXN</a>).
Price Action: OXY shares are up 6.11% at $41.40 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/45284262" target="_blank" rel="noreferrer noopener">Exxon Mobil Says Deal With Japan&#8217;s Marubeni To Boost Global Energy Supply</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

FTXN

OILT

Neutral Territory For Occidental? JPMorgan Weighs Strong Q1 Against Future Challenges

Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) will release its quarterly earnings report on Friday, 2025-05-09. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Telos to report an earnings per share (EPS) of $-0.05.
The market awaits Telos's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.05, leading to a 0.38% drop in the share price on the subsequent day.
Here's a look at Telos's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.09</td>
<td>-0.14</td>
<td>-0.14</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.10</td>
<td>-0.09</td>
<td>-0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-5.0%</td>
<td>-47.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746723775_0.png" alt="eps graph" />
<h3>Telos Share Price Analysis</h3>
Shares of Telos were trading at $2.49 as of May 07. Over the last 52-week period, shares are down 27.63%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Telos</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Telos.
Analysts have provided Telos with 3 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $3.83, suggesting a potential 53.82% upside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Silvaco Group, Duos Technologies Group and Arteris, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Silvaco Group, with an average 1-year price target of $17.0, suggesting a potential 582.73% upside.</li>
<li>Analysts currently favor an Buy trajectory for Duos Technologies Group, with an average 1-year price target of $9.0, suggesting a potential 261.45% upside.</li>
<li>Analysts currently favor an Buy trajectory for Arteris, with an average 1-year price target of $15.33, suggesting a potential 515.66% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Silvaco Group, Duos Technologies Group and Arteris, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telos</td>
<td>Neutral</td>
<td>-35.77%</td>
<td>$10.62M</td>
<td>-7.27%</td>
</tr>
<tr>
<td>Silvaco Group</td>
<td>Buy</td>
<td>43.03%</td>
<td>$15.44M</td>
<td>4.18%</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>Buy</td>
<td>-4.27%</td>
<td>$-329.95K</td>
<td>-142.71%</td>
</tr>
<tr>
<td>Arteris</td>
<td>Buy</td>
<td>23.87%</td>
<td>$13.91M</td>
<td>-1607.05%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Telos ranks at the bottom for Revenue Growth and Gross Profit, indicating negative growth and profit. It also has the lowest Return on Equity among its peers, reflecting poor performance in generating profit from shareholders' equity. Overall, Telos lags behind its peers in key financial metrics.
<h3>Get to Know Telos Better</h3>
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
<h3>Unraveling the Financial Story of Telos</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Telos's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -35.77%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Telos's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -35.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Telos's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.27% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Telos's ROA excels beyond industry benchmarks, reaching -5.75%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.08, Telos adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/TLS/earnings">To track all earnings releases for Telos visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

What's Next: Telos's Earnings Preview

Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is preparing to release its quarterly earnings on Friday, 2025-05-09. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Rapid Micro Biosystems to report an earnings per share (EPS) of $-0.27.
The announcement from Rapid Micro Biosystems is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 0.0% drop in the share price the following trading session.
Here's a look at Rapid Micro Biosystems's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.22</td>
<td>-0.25</td>
<td>-0.28</td>
<td>-0.29</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.22</td>
<td>-0.26</td>
<td>-0.29</td>
<td>-0.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>2.0%</td>
<td>17.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746723764_0.png" alt="eps graph" />
<h3>Rapid Micro Biosystems Share Price Analysis</h3>
Shares of Rapid Micro Biosystems were trading at $2.32 as of May 07. Over the last 52-week period, shares are up 215.0%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Views on Rapid Micro Biosystems</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Rapid Micro Biosystems.
Analysts have provided Rapid Micro Biosystems with 1 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $8.0, suggesting a potential 244.83% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Champions Oncology, Akoya Biosciences and Harvard Bioscience, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Champions Oncology, with an average 1-year price target of $12.0, suggesting a potential 417.24% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Akoya Biosciences, with an average 1-year price target of $2.19, suggesting a potential 5.6% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Harvard Bioscience, with an average 1-year price target of $4.5, suggesting a potential 93.97% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Champions Oncology, Akoya Biosciences and Harvard Bioscience, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid Micro Biosystems</td>
<td>Outperform</td>
<td>29.68%</td>
<td>$981K</td>
<td>-12.10%</td>
</tr>
<tr>
<td>Champions Oncology</td>
<td>Buy</td>
<td>41.77%</td>
<td>$10.42M</td>
<td>146.18%</td>
</tr>
<tr>
<td>Akoya Biosciences</td>
<td>Neutral</td>
<td>-19.42%</td>
<td>$14.39M</td>
<td>-77.25%</td>
</tr>
<tr>
<td>Harvard Bioscience</td>
<td>Outperform</td>
<td>-12.78%</td>
<td>$14.01M</td>
<td>0.03%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Rapid Micro Biosystems ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity. Overall, Rapid Micro Biosystems is positioned in the middle compared to its peers based on the provided metrics.
<h3>Get to Know Rapid Micro Biosystems Better</h3>
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
<h3>Rapid Micro Biosystems's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Rapid Micro Biosystems's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 29.68%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Rapid Micro Biosystems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -117.62%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Rapid Micro Biosystems's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Rapid Micro Biosystems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -9.48%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.08, Rapid Micro Biosystems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/RPID/earnings">To track all earnings releases for Rapid Micro Biosystems visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RPID

Rapid Micro Biosystems's Earnings Outlook

American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is preparing to release its quarterly earnings on Friday, 2025-05-09. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect American Strategic to report an earnings per share (EPS) of $-2.01.
American Strategic bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at American Strategic's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td>-2.62</td>
<td>-2.99</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.6</td>
<td>-2.62</td>
<td>-2.84</td>
<td>-3.28</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>0.0%</td>
<td>2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<h3>American Strategic Share Price Analysis</h3>
Shares of American Strategic were trading at $11.66 as of May 06. Over the last 52-week period, shares are up 42.8%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/NYC/earnings">To track all earnings releases for American Strategic visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of American Strategic's Earnings

RBC Capital analyst Brad Heffern maintains AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) with a Sector Perform and lowers the price target from $223 to $220.

RBC Capital Maintains Sector Perform on AvalonBay Communities, Lowers Price Target to $220

AMC Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) is preparing to release its quarterly earnings on Friday, 2025-05-09. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect AMC Networks to report an earnings per share (EPS) of $0.81.
Anticipation surrounds AMC Networks's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.41, which was followed by a 0.0% drop in the share price the next day.
Here's a look at AMC Networks's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.05</td>
<td>0.62</td>
<td>1.52</td>
<td>1.67</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.64</td>
<td>0.91</td>
<td>1.24</td>
<td>1.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>3.0%</td>
<td>-5.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746723737_0.png" alt="eps graph" />
<h3>Performance of AMC Networks Shares</h3>
Shares of AMC Networks were trading at $6.63 as of May 07. Over the last 52-week period, shares are down 51.21%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AMCX/earnings">To track all earnings releases for AMC Networks visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMCX

An Overview of AMC Networks's Earnings

Press Releases

SaverOne to Deploy Driver Safety Systems Across Oz Group's Fleet

SaverOne Announces $1.5 Million Registered Direct Offering

SaverOne Announces New Deployment of Its Driver Distraction Prevention System in Teva Pharmaceutical's Truck Fleet

SaverOne Announces First U.S. Commercial Agreement with FedEx Trucking Contractor MDM Express

SaverOne Implements Change in Ratio of Shares to ADSs to Meet Nasdaq Minimum Bid Price Requirement

SaverOne Granted New Patent in the United States  Further Expanding its IP Portfolio

SaverOne Regains Compliance with Nasdaq Minimum Bid Price Requirement

SaverOne Reports Full Year 2024 Results

SaverOne Signs New Distribution Agreement in Canada

Contracts

SaverOne Signs Expands Cooperation with Cemex: Signs Agreement with Cemex Czech Republic for Deployment of Its Driver Distraction Prevention System

SVRE

Astrotech

Cemtrex

Digital Ally

Electro-Sensors

Focus Universal

AEye

MultiSensor AI Holdings, Inc. - Common Stock

MultiSensor AI Holdings

Maris Tech

SMX (Security Matters) Public Limited Company - Class A Ordinary Shares

SMX (Security Matters)

Sobr Safe

ScanTech AI Systems

Universal Security Instruments, Inc. Common Stock

Universal Security

VerifyMe

Screenshot 2024-03-28 at 5.39.42 PM

Markets

VLVLY

SaverOne Inks Major OEM Deal With IVECO – Distracted Driving Software To Be Installed In All Its Light, Medium And Heavy Commercial Vehicles

Comments

Saverone 2014

Actualités

Dernières nouvelles pour Saverone 2014 (NASDAQ:SVRE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL